Results 71 to 80 of about 1,126 (138)

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, Volume 32, Issue 5, Page 1188-1199, September/October 2026.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Validación de un método para la cuantificación plasmática de emicizumab

, 2023
Introduction: Emicizumab (Hemlibra®, ROCHE) is a bispecific, recombinant and humanized IgG4 monoclonal antibody, that mimics the function of FVIIIa. Its subcutaneous administration is effective and safe in preventing bleeding in patients with severe ...
Annetta, E, Sueldo, R.E., Frontroth, J.P., Bianco, B, Hepner, M, Cervio, C, Sciuccati, G   +6 more
core  

Standard curves required for emicizumab quantification.

, 2022
Typical standard curves resulted from different emicizumab concentrations in (A) manual and (B) automated format. Data were collected for manual configuration in triplicate and for automated configuration in duplicate showed as the means ± s.d. (TIF)
Johannes Oldenburg (138185), Jens Müller (263387), Bernd Pötzsch (615446), Nasim Shahidi Hamedani (13046936)   +3 more
core   +1 more source

Plasma emicizumab concentrations and bleeding rates in children and adults with severe hemophilia A

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab has been in clinical use for less than 10 years. Real-world experience is still needed to guide its use for optimal safety, efficacy, and resource efficiency.
Jerome Teitel, Manuel Carcao, Michelle Sholzberg, Rowan Thillaye-Kerr, Vidushi Swarup, Teodora Markovic, Vanessa Bouskill   +6 more
doaj   +1 more source

Clinical Experience with Emicizumab and Rituximab as First-Line Treatment in a Case Series of Acquired Hemophilia A

Hematology Reports
Background: Acquired hemophilia A (AHA) is a bleeding disorder caused by autoantibodies against coagulation factor VIII. Treatment includes controlling bleeding and eliminating the inhibitor.
Hikari Ota, Kyohei Yasuda, Namie Toyota, Kazuhiro Masuoka   +3 more
doaj   +1 more source

PO043 | MULTICENTRE REAL‑WORLD EXPERIENCE OF EMICIZUMAB PROPHYLAXIS IN AN ITALIAN COHORT OF 49 CHILDREN WITH SEVERE HEMOPHILIA A - EMIPED STUDY

Bleeding, Thrombosis and Vascular Biology
Background. Emicizumab prophylaxis is approved for people of all ages with hemophilia A (HA) with and without inhibitors. Efficacy and tolerability of emicizumab have been evaluated in children and adolescents in phase III studies and the HAVEN 7 phase ...
Lisa Pieri
doaj  

Emicizumab prophylaxis in current haemophilia A care in the Czech Republic—data from the Czech National Haemophilia Programme Registry

Research and Practice in Thrombosis and Haemostasis
Background: Nonfactor therapy with emicizumab has become an important part of the haemophilia A treatment landscape recently. Objectives: We aimed to analyze data on the transition from previous treatment regimens to emicizumab in routine clinical ...
Ester Zápotocká, Petra Ovesná, Bohumír Blažek, Zuzana Čermáková, Zdeňka Hajšmanová, Radomíra Hrdličková, Petr Birke, Daniela Procházková, Petr Smejkal, Jan Blatný   +9 more
doaj   +1 more source

Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.

, 2020
COVID-19 can be associated with coagulopathy (CAC, COVID-19-associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways. Emerging
Álvarez-Román, María Teresa, García-Barcenilla, Sara, Rivas-Pollmar, María Isabel, Butta-Coll, Nora V, Martín Salces, Mónica, Jiménez-Yuste, Victor   +5 more
core   +1 more source

CO-80 | EMICIZUMAB PLASMA CONCENTRATIONS AND CLINICAL OUTCOMES IN ACQUIRED HEMOPHILIA A: A REAL-WORLD SINGLE-CENTER EXPERIENCE

Bleeding, Thrombosis and Vascular Biology
Background and Aims. Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder associated with significant bleeding morbidity. The AGEHA study established a standardized emicizumab dosing regimen for AHA, but data on plasma drug concentrations ...
Chiara Simion
doaj  

Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis

Haematologica
Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against factor VIII (FVIII). Emicizumab mimics the activity of FVIIIa restoring thrombin generation.
Fabius J. Pelzer, Ella I. Ertekin, Olga Oleshko, Annika Klingberg, Paul Knöbl, Christian Pfrepper, Richard Greil, Johannes Oldenburg, Ulrich J. Sachs, Wolfgang Miesbach, Karolin Trautmann-Grill, Katharina Holstein, Hermann Eichler, Patrick Möhnle, Christina Hart, Robert Klamroth, Andreas Tiede, Sonja Werwitzke   +17 more
doaj   +1 more source